Prometic gains on rare pediatric disease designation

Prometic Life Sciences Inc. (TSX:PLI; OTCQX:PFSCF) said FDA granted rare pediatric disease designation to Ryplazym to treat congenital plasminogen deficiency. The company gained C$0.30 (25%) to C$1.50 in Toronto on Tuesday, and $0.22 (22%) to $1.20 on OTC.

The human plasma-derived plasminogen also has Orphan Drug and Fast Track designations from FDA...